Event > Conference >
Join us at AASLD 2023 to discuss the latest research on disease states like NAFLD, NASH, and Hepatitis. Will you be there too?
Learn more below…
See educational sessions from leading hepatologists and public health experts or delve deep with a niche session from one of the leading minds in the Meet-the-Expert sessions. The patient’s perspective will also be presented by the Patient Advocacy Group programming.
Head to our exhibition stand – 3134
Our dedicated team will be available to answer questions and share over a decade of organ-on-a-chip (OOC) expertise with you at AASLD 2023!
We look forward to introducing you to our PhysioMimix® suite of microphysiological systems, consumables, assay protocols and contract research services. Discover how our solutions deliver clinically relevant mechanistic data that enables you to design cost-efficient in vivo studies (using fewer animals) and improve your ability to predict clinical outcomes for therapeutics targeting common liver diseases inc., NAFLD/NASH.
Poster presentation – Poster #2296-C
Developing a Translational Biomarker Panel for Use in Pre-clinical Advanced in Vitro Studies of Non-alcoholic Steatohepatitis
Presenter Dr Yassen Abbas, Lead Scientist
Saturday, November 11th 1-2pm | Hall C.
Our Team at AASLD 2023
Dr Tomasz Kostrzewski, CN Bio’s CSO, has more than 15 years of experience in molecular and cellular biology research. Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences, studying immune cell development and stem cell differentiation. At Imperial College London, he completed both an MRes and a PhD in the Cell and Molecular Biology department. He has significant experience in advanced (3D) mammalian cell culture, gene expression analysis and immune cell function. Additionally, he has previous experience working in biopharmaceutical drug discovery and development with GlaxoSmithKline. In 2017, he was promoted to head of biology at CN Bio and is responsible for biological model development and collaborative research projects. In 2022, he took responsibility for all technical activities, including developing new products, technologies, and assays. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. Dr Kostrzewski has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Dr Scott Chilton is the Eastern US Sales Manager for CN Bio, based in Massachusetts, USA. Scott supports researchers who want to develop safe and effective therapeutics faster and more cost-effectively by adopting solutions that provide physiologically relevant and clinically translatable data. Scott holds a PhD from Harvard University and a BS from Massachusetts Institute of Technology.
Dr. Anthony Berger is CN-Bio’s US-based Field Application Scientist, providing support for the PhysioMimix® Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).
Dr. Yassen Abbas is a Lead Scientist at CN Bio Innovations. He completed an MEng in chemical engineering at The University of Edinburgh and joined the European Space Agency as a graduate engineer. He later received a PhD from the University of Cambridge and completed a postdoc fellowship, also at Cambridge on the development of a tissue engineered model of the human endometrium. He has experience with real-time sensor technology, organoids and development of in vitro tissue models using human primary cells. Dr Abbas has published five peer-reviewed scientific articles, four as first author.